Arizona Tribune

NYSE - LSE

RBGPF	0.12%	82.5	$
CMSC	-0.17%	23.72	$
RYCEF	4.19%	16.7	$
NGG	-0.89%	84.52	$
BTI	0.33%	60.88	$
SCS	0.12%	16.14	$
RELX	-0.73%	35.54	$
GSK	1.45%	52.36	$
VOD	1.53%	14.877	$
AZN	-0.27%	189.93	$
RIO	1.13%	92.07	$
CMSD	0.04%	24.06	$
BCC	2.07%	82.52	$
JRI	0.61%	13.16	$
BP	-0.46%	37.705	$
BCE	-0.76%	25.665	$

Featured

Punctuality at Germany's crisis-hit railway slumps

Punctuality at Germany's much-maligned state railway Deutsche Bahn slumped even further in January, the company said Monday, adding to the network's woes.

Oil slides, gold loses lustre as Iran threat recedes

Oil and gold prices fell as concerns eased over US monetary policy and the chances of an American attack on Iran, while stock markets pushed higher.

Last news

US airlines warn of 'chaos' if 5G not limited near airports: letter

The chief executives of America's largest airlines warned ahead of Wednesday's 5G service rollout that the technology should be limited near US airports, or risk "significant operational disruption" to travel and shipping.

Unexpected star of gay rights best-seller, Pence family rabbit dies

The family of former US vice president Mike Pence has announced the death of Marlon Bundo, their pet rabbit who starred in a children's book series by the second family as well as a parody version supporting gay rights.

Credit Suisse chief quits over Covid rules breach

The chairman of Credit Suisse resigned Monday over Covid quarantine violations, leaving the bank's new risk committee chief holding the reins and tasked with trying to stabilise the scandal-hit institution.

European stocks rise tracking big corporate news, China growth

European stock markets climbed on Monday as China's unexpectedly muted growth slowdown and optimism over the impact of the Omicron coronavirus variant boosted investor confidence.

Canada health authority approves Pfizer's anti-Covid pill

Canada's health authority said Monday it has approved Pfizer's anti-Covid pill, Paxlovid, for adults at high risk of progressing to serious disease.

Covid-flu joint booster jab possible late 2023: Moderna

Moderna aims to roll out a combined Covid-flu-RSV booster vaccine in late 2023, the US pharmaceutical firm said Monday, hoping a joint jab would encourage people to get an annual shot.

Arizona Tribune - Economy (English)